Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Armata Pharmaceuticals ( (ARMP) ) has issued an announcement.
At the Annual Meeting of Shareholders on June 12, 2025, Armata Pharmaceuticals elected seven board members for a one-year term ending in 2026. Shareholders also approved the compensation of the company’s executive officers and ratified Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (ARMP) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Armata Pharmaceuticals stock, see the ARMP Stock Forecast page.
Spark’s Take on ARMP Stock
According to Spark, TipRanks’ AI Analyst, ARMP is a Neutral.
Armata Pharmaceuticals’ overall score is primarily impacted by its financial distress, with persistent losses and negative equity. However, recent positive trial results and strategic financing provide a potential turning point, with technical indicators showing some short-term bullish momentum.
To see Spark’s full report on ARMP stock, click here.
More about Armata Pharmaceuticals
Armata Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development of bacteriophage-based therapies to treat antibiotic-resistant infections.
Average Trading Volume: 247,050
Technical Sentiment Signal: Sell
Current Market Cap: $73.47M
For a thorough assessment of ARMP stock, go to TipRanks’ Stock Analysis page.